Abbott's test is designed to detect two proteins — GFAP and UCH-L1 — that are released from the brain into the bloodstream following brain injury.
The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.
The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.
In a newly published study, an algorithm developed at NIH shows promise for improving early detection of cervical cancer in low-resource areas, where 80 percent of cases occur.
New drugs, tests, and policies suggest steady and continued future growth in the space, though public awareness of personalized medicine continues to lag.
Excluding IPOs, the funding environment for private venture-backed financing Dx deals in the US and Europe was remarkably similar in 2018 to 2017, according to Silicon Valley Bank.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
The National Institutes of Health Commercial Accelerator Program helps small healthcare and life science companies bring their products to market.
IQuity develops tests that use RNA expression data to predict, detect, and monitor disease, as well as stratify patients by severity of disease.
The grants include funding for five new clinical sites, a new metabolomics core, and increased model organism capabilities.